Ecopetrol
EC
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
Meta Platforms
META
Adobe
ADBE
US Stock MarketDetailed Quotes
SRPT Sarepta Therapeutics
- 121.500
- -1.870-1.52%
Close Dec 27 16:00 ET
- 121.500
- 0.0000.00%
Post 20:01 ET
11.61BMarket Cap78.90P/E (TTM)
123.574High120.830Low478.25KVolume122.240Open123.370Pre Close58.21MTurnover0.53%Turnover RatioLossP/E (Static)95.52MShares173.25052wk High9.50P/B11.07BFloat Cap91.34452wk Low--Dividend TTM91.15MShs Float181.830Historical High--Div YieldTTM2.22%Amplitude2.598Historical Low121.714Avg Price1Lot Size
About Sarepta Therapeutics Company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Company Profile
SymbolSRPT
Company NameSarepta Therapeutics
Listing DateJun 4, 1997
Issue Price9.00
Founded1980
CEOMr. Christopher Garabedian
MarketNASDAQ
Employees1314
Fiscal Year Ends12-31
Address215 First Street,Suite 415
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142
Phone1-617-274-4000
Websitehttp://www.sarepta.com
Company Executives
- Name
- Position
- Salary
- Douglas S. Ingram,Esq.
- Director, President and Chief Executive Officer
- 1.66M
- Dallan Murray
- Executive Vice President and Chief Customer Officer
- --
- Ian Michael Estepan
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- 3.71M
- Louise Rodino-Klapac
- Executive Vice President, Head of R&D and Chief Scientific Officer
- 3.72M
- Bilal Arif
- Executive Vice President and Chief Technical Operations Officer
- 3.52M
- Cristin Rothfuss
- Executive Vice President and General Counsel
- --
- Deirdre P. Connelly
- Director
- --
- Dr. Claude Nicaise,M.D.
- Independent Director
- 553.34K
- Richard J. Barry
- Independent Director
- 563.65K
- Michael Chambers
- Independent Director
- 533.99K
- Dr. Stephen L. Mayo, PhD
- Independent Director
- 546.49K
- Dr. Hans Wigzell, M.D.,PhD
- Independent Director
- 546.99K
- Dr. Kathryn Jean Boor, PhD
- Independent Director
- 543.58K
- Dr. M. Kathleen Behrens Wilsey, PhD
- Chairwoman of the Board
- 594.99K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.